Philip Morris rises as IQOS regulatory clarity and smoke-free growth narrative stay in focus

Philip Morris International Inc. (PM) is up 3.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The move likely reflects renewed investor focus on U.S. regulatory clarity for IQOS and PMI’s broader smoke-free growth story, following recent FDA actions and company updates. With IQOS and other smoke-free products positioned as key earnings drivers, any sign of reduced regulatory uncertainty can support a higher valuation multiple.

Details:

The FDA renewed authorization for five IQOS products to be marketed with exposure modification claims, a development that supports continued U.S. marketing of IQOS-related reduced-exposure messaging for adult consumers.

PMI announced the U.S. FDA reauthorization of IQOS as a Modified Risk Tobacco Product (MRTP), highlighting that the renewal allows it to continue communicating reduced-exposure information to U.S. adults 21+ who use traditional tobacco products.

In its April 22, 2026 first-quarter update, PMI emphasized continued momentum in IQOS volumes and market share in key regions and maintained/updated its 2026 adjusted EPS forecast for currency only, reinforcing the durability of its smoke-free-led growth profile.

This could also be helped by “defensive” rotation into consumer staples on a risk-off tape, which often benefits large dividend-paying tobacco names even without a single breaking headline.

Sources:

U.S. Food and Drug Administration, Philip Morris International, U.S. Securities and Exchange Commission

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive PM Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$PM Hedge Fund Activity

We have seen 1,324 institutional investors add shares of $PM stock to their portfolio, and 1,210 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 15,976,947 shares (-74.7%) from their portfolio in Q4 2025, for an estimated $2,562,702,298
CAPITAL INTERNATIONAL INVESTORS added 12,227,004 shares (+13.7%) to their portfolio in Q4 2025, for an estimated $1,961,211,441
CAPITAL RESEARCH GLOBAL INVESTORS added 11,013,173 shares (+25.3%) to their portfolio in Q4 2025, for an estimated $1,766,512,949
JPMORGAN CHASE & CO removed 5,542,623 shares (-11.7%) from their portfolio in Q4 2025, for an estimated $889,036,729
VIKING GLOBAL INVESTORS LP removed 4,426,128 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $709,950,931
DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN removed 4,331,283 shares (-81.5%) from their portfolio in Q4 2025, for an estimated $694,737,793
BLACKROCK, INC. added 3,991,412 shares (+3.8%) to their portfolio in Q4 2025, for an estimated $640,222,484

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$PM Congressional Stock Trading

Members of Congress have traded $PM stock 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $PM stock by members of Congress over the last 6 months:

REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 02/05.
REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$PM Analyst Ratings

Wall Street analysts have issued reports on $PM in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

JP Morgan issued a "Overweight" rating on 11/26/2025
Barclays issued a "Overweight" rating on 11/17/2025

To track analyst ratings and price targets for $PM, check out Quiver Quantitative's $PM forecast page.

$PM Price Targets

Multiple analysts have issued price targets for $PM recently. We have seen 8 analysts offer price targets for $PM in the last 6 months, with a median target of $187.5.

Here are some recent targets:

Gerald Pascarelli from Needham set a target price of $200.0 on 04/23/2026
Eric Serotta from Morgan Stanley set a target price of $190.0 on 04/17/2026
Faham Baig from UBS set a target price of $168.0 on 04/17/2026
Matthew Smith from Stifel set a target price of $195.0 on 04/10/2026
Simon Hales from Citigroup set a target price of $210.0 on 02/10/2026
Edward Mundy from Jefferies set a target price of $180.0 on 01/20/2026
Jared Dinges from JP Morgan set a target price of $185.0 on 11/26/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.